Abstract:Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) are debilitating neurodegenerative diseases with shared pathological features like transactive response DNA-binding protein of 43 kDa (TDP-43) inclusions and genetic mutations. Both diseases involve synaptic dysfunction, contributing to their clinical features. Synaptic biomarkers, representing proteins associated with synaptic function or structure, offer insights into disease mechanisms, progression, and treatment responses. These biomarkers can detect disease early, track its progression, and evaluate therapeutic efficacy. ALS is characterized by elevated neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF) and blood, correlating with disease progression. TDP-43 is another key ALS biomarker, its mislocalization linked to synaptic dysfunction. In FTD, TDP-43 and tau proteins are studied as biomarkers. Synaptic biomarkers like neuronal pentraxins (NPs), including neuronal pentraxin 2 (NPTX2), and neuronal pentraxin receptor (NPTXR), offer insights into FTD pathology and cognitive decline. Advanced technologies, like machine learning (ML) and artificial intelligence (AI), aid biomarker discovery and drug development. Challenges in this research include technological limitations in detection, variability across patients, and translating findings from animal models. ML/AI can accelerate discovery by analyzing complex data and predicting disease outcomes. Synaptic biomarkers offer early disease detection, personalized treatment strategies, and insights into disease mechanisms. While challenges persist, technological advancements and interdisciplinary efforts promise to revolutionize the understanding and management of ALS and FTD. This review will explore the present comprehension of synaptic biomarkers in ALS and FTD and discuss their significance and emphasize the prospects and obstacles.

Pathological insights derived from neuroimaging in amyotrophic lateral sclerosis: emerging clinical applications

Potential of neuroimaging as a biomarker in amyotrophic lateral sclerosis: from structure to metabolism

Amyotrophic Lateral Sclerosis: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Therapies

Biomarkers in amyotrophic lateral sclerosis: current status and future prospects

Hippocampal Subfield and Anterior-Posterior Segment Volumes in Patients with Sporadic Amyotrophic Lateral Sclerosis

Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis

Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis

Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis

Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis

Cortical influences drive amyotrophic lateral sclerosis

Improving clinical trial outcomes in amyotrophic lateral sclerosis

Network spreading and local biological vulnerability in amyotrophic lateral sclerosis

Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets

Towards an integrated approach for understanding glia in Amyotrophic Lateral Sclerosis

Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

Quantifying disease progression in amyotrophic lateral sclerosis

Emerging perspectives of synaptic biomarkers in ALS and FTD

Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis

Subcortical grey matter involvement in ALS and PLS – vulnerable hubs of cortico-cortical and cortico-basal circuits: extrapyramidal, cognitive, bulbar and respiratory correlates

Pathophysiological and diagnostic implications of cortical dysfunction in ALS

Tracing ALS Degeneration: Insights from Spinal Cord and Cortex Transcriptomes